188 related articles for article (PubMed ID: 8584586)
1. Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies.
Schooler NR; Keith SJ; Severe JB; Matthews SM
Psychiatr Q; 1995; 66(4):279-92. PubMed ID: 8584586
[TBL] [Abstract][Full Text] [Related]
2. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.
Schooler NR; Keith SJ; Severe JB; Matthews SM; Bellack AS; Glick ID; Hargreaves WA; Kane JM; Ninan PT; Frances A; Jacobs M; Lieberman JA; Mance R; Simpson GM; Woerner MG
Arch Gen Psychiatry; 1997 May; 54(5):453-63. PubMed ID: 9152099
[TBL] [Abstract][Full Text] [Related]
3. Strategies for enhancing drug therapy of schizophrenia.
Schooler NR; Levine J
Am J Psychother; 1983 Oct; 37(4):521-32. PubMed ID: 6140869
[TBL] [Abstract][Full Text] [Related]
4. [Detection of early warning signs in schizophrenic patients. Possible applications in prevention of recurrence].
Wiedemann G; Hahlweg K; Hank G; Feinstein E; Müller U; Dose M
Nervenarzt; 1994 Jul; 65(7):438-43. PubMed ID: 7800087
[TBL] [Abstract][Full Text] [Related]
5. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies.
Gaebel W; Jänner M; Frommann N; Pietzcker A; Köpcke W; Linden M; Müller P; Müller-Spahn F; Tegeler J
Schizophr Res; 2002 Jan; 53(1-2):145-59. PubMed ID: 11728846
[TBL] [Abstract][Full Text] [Related]
6. Maintenance therapy of persons with schizophrenia.
Carpenter WT
J Clin Psychiatry; 1996; 57 Suppl 9():10-8. PubMed ID: 8823345
[TBL] [Abstract][Full Text] [Related]
7. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
[TBL] [Abstract][Full Text] [Related]
8. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention.
Francey SM; Nelson B; Thompson A; Parker AG; Kerr M; Macneil C; Fraser R; Hughes F; Crisp K; Harrigan S; Wood SJ; Berk M; McGorry PD
Schizophr Res; 2010 Jun; 119(1-3):1-10. PubMed ID: 20347270
[TBL] [Abstract][Full Text] [Related]
9. Dose response of prophylactic antipsychotics.
Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
[TBL] [Abstract][Full Text] [Related]
10. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
[TBL] [Abstract][Full Text] [Related]
11. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
Shriqui CL
Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
[TBL] [Abstract][Full Text] [Related]
12. Cost of relapse in schizophrenia.
Weiden PJ; Olfson M
Schizophr Bull; 1995; 21(3):419-29. PubMed ID: 7481573
[TBL] [Abstract][Full Text] [Related]
13. Early, targeted pharmacotherapeutic intervention in schizophrenia.
Carpenter W
J Clin Psychiatry; 1986 May; 47 Suppl():23-9. PubMed ID: 2871012
[TBL] [Abstract][Full Text] [Related]
14. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
Hogarty GE
J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
[TBL] [Abstract][Full Text] [Related]
15. High-dose antipsychotic medication.
Will D; Wrate RM; Bhate S; Taylor P; James T; Rothery D; Clark A
Br J Psychiatry; 1994 Aug; 165(2):269-70. PubMed ID: 7953047
[No Abstract] [Full Text] [Related]
16. Intermittent medication, coping and psychotherapy. Interactions in relapse prevention and course modification.
Müller P; Bandelow B; Gaebel W; Köpcke W; Linden M; Müller-Spahn F; Pietzcker A; Schaefer E; Tegeler J
Br J Psychiatry Suppl; 1992 Oct; (18):140-4. PubMed ID: 1356364
[No Abstract] [Full Text] [Related]
17. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.
Leucht S; Heres S
J Clin Psychiatry; 2006; 67 Suppl 5():3-8. PubMed ID: 16822090
[TBL] [Abstract][Full Text] [Related]
18. [Rehabilitation in schizophrenia--guidelines for including psychosocial measures].
Katschnig H
Wien Med Wochenschr; 1998; 148(11-12):273-80. PubMed ID: 9746970
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive psychosocial therapies for the treatment of schizophrenia.
Patterson TL; Leeuwenkamp OR
Schizophr Res; 2008 Mar; 100(1-3):108-19. PubMed ID: 18226500
[TBL] [Abstract][Full Text] [Related]
20. Integration of family and drug treatment strategies in the treatment of schizophrenia: a selective review.
Schooler NR
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():73-80. PubMed ID: 8866768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
